Fate Therapeutics Book Value Per Share Growth & History (FATE)
Fate Therapeutics's book value per share was $1.80 for fiscal 2025.
View full Fate Therapeutics company overviewFate Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.80 | -$1.00 | −35.80% |
| 2024 | 2024-12-31 | $2.80 | -$0.94 | −25.11% |
| 2023 | 2023-12-31 | $3.74 | -$1.24 | −24.90% |
| 2022 | 2022-12-31 | $4.97 | -$2.12 | −29.86% |
| 2021 | 2021-12-31 | $7.09 | $2.71 | +61.81% |
| 2020 | 2020-12-31 | $4.38 | $1.15 | +35.60% |
| 2019 | 2019-12-31 | $3.23 | $0.75 | +30.30% |
| 2018 | 2018-12-31 | $2.48 | $1.01 | +69.19% |
| 2017 | 2017-12-31 | $1.47 | -$0.30 | −17.06% |
| 2016 | 2016-12-31 | $1.77 | $0.44 | +33.44% |
| 2015 | 2015-12-31 | $1.32 | -$0.05 | −3.86% |
| 2014 | 2014-12-31 | $1.38 | -$1.11 | −44.63% |
| 2013 | 2013-12-31 | $2.49 | $42.08 | — |
| 2012 | 2012-12-31 | -$39.60 | $21.40 | — |
| 2011 | 2011-12-31 | -$60.99 | — | — |
Fate Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.31 | -$0.96 | −42.32% |
| Q1 2026 | 2026-03-31 | $1.55 | -$0.97 | −38.58% |
| Q4 2025 | 2025-12-31 | $1.80 | -$1.00 | −35.80% |
| Q3 2025 | 2025-09-30 | $2.03 | -$1.15 | −36.21% |
| Q2 2025 | 2025-06-30 | $2.28 | -$1.21 | −34.63% |
| Q1 2025 | 2025-03-31 | $2.52 | -$1.23 | −32.79% |
| Q4 2024 | 2024-12-31 | $2.80 | -$0.94 | −25.11% |
| Q3 2024 | 2024-09-30 | $3.18 | -$0.90 | −22.13% |
| Q2 2024 | 2024-06-30 | $3.49 | -$0.96 | −21.52% |
| Q1 2024 | 2024-03-31 | $3.74 | -$1.12 | −23.00% |
| Q4 2023 | 2023-12-31 | $3.74 | -$1.24 | −24.90% |
| Q3 2023 | 2023-09-30 | $4.09 | -$1.25 | −23.41% |
| Q2 2023 | 2023-06-30 | $4.44 | -$1.55 | −25.86% |
| Q1 2023 | 2023-03-31 | $4.86 | -$1.70 | −25.89% |
| Q4 2022 | 2022-12-31 | $4.97 | -$2.12 | −29.86% |
| Q3 2022 | 2022-09-30 | $5.33 | -$2.32 | −30.35% |
| Q2 2022 | 2022-06-30 | $5.99 | -$1.99 | −24.89% |
| Q1 2022 | 2022-03-31 | $6.56 | -$1.85 | −22.03% |
| Q4 2021 | 2021-12-31 | $7.09 | $2.71 | +61.81% |
| Q3 2021 | 2021-09-30 | $7.66 | $2.78 | +57.02% |
| Q2 2021 | 2021-06-30 | $7.98 | $2.52 | +46.07% |
| Q1 2021 | 2021-03-31 | $8.42 | $5.53 | +191.73% |
| Q4 2020 | 2020-12-31 | $4.38 | $1.15 | +35.60% |
| Q3 2020 | 2020-09-30 | $4.88 | $1.32 | +37.23% |
| Q2 2020 | 2020-06-30 | $5.46 | $3.51 | +179.73% |
| Q1 2020 | 2020-03-31 | $2.88 | $0.64 | +28.80% |
| Q4 2019 | 2019-12-31 | $3.23 | $0.75 | +30.30% |
| Q3 2019 | 2019-09-30 | $3.55 | $0.86 | +31.81% |
| Q2 2019 | 2019-06-30 | $1.95 | $0.98 | +101.16% |
| Q1 2019 | 2019-03-31 | $2.24 | $1.01 | +82.15% |
| Q4 2018 | 2018-12-31 | $2.48 | $1.01 | +69.19% |
| Q3 2018 | 2018-09-30 | $2.70 | $1.59 | +144.36% |
| Q2 2018 | 2018-06-30 | $0.97 | -$0.36 | −27.19% |
| Q1 2018 | 2018-03-31 | $1.23 | -$0.31 | −20.28% |
| Q4 2017 | 2017-12-31 | $1.47 | -$0.30 | −17.06% |
| Q3 2017 | 2017-09-30 | $1.10 | $0.36 | +48.51% |
| Q2 2017 | 2017-06-30 | $1.33 | $0.53 | +66.47% |
| Q1 2017 | 2017-03-31 | $1.54 | $0.48 | +44.87% |
| Q4 2016 | 2016-12-31 | $1.77 | $0.44 | +33.44% |
| Q3 2016 | 2016-09-30 | $0.74 | -$0.82 | −52.58% |
| Q2 2016 | 2016-06-30 | $0.80 | -$0.98 | −55.13% |
| Q1 2016 | 2016-03-31 | $1.06 | $0.03 | +3.39% |
| Q4 2015 | 2015-12-31 | $1.32 | -$0.05 | −3.86% |
| Q3 2015 | 2015-09-30 | $1.57 | -$0.07 | −4.04% |
| Q2 2015 | 2015-06-30 | $1.78 | -$0.14 | −7.42% |
| Q1 2015 | 2015-03-31 | $1.03 | -$1.18 | −53.36% |
| Q4 2014 | 2014-12-31 | $1.38 | -$1.11 | −44.63% |
| Q3 2014 | 2014-09-30 | $1.63 | $49.83 | — |
| Q2 2014 | 2014-06-30 | $1.93 | — | — |
| Q1 2014 | 2014-03-31 | $2.21 | — | — |
| Q4 2013 | 2013-12-31 | $2.49 | $42.08 | — |
| Q3 2013 | 2013-09-30 | -$48.20 | — | — |
| Q4 2012 | 2012-12-31 | -$39.60 | — | — |
Fate Therapeutics book value per share trends
Over the last five fiscal years, Fate Therapeutics's book value per share decreased from $4.38 to $1.80, a change of -$2.59. The latest reported quarter, Q2 2026, shows $1.31.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Fate Therapeutics source filings ↗